Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. reports developments tied to its clinical-stage oncology pipeline, led by Plinabulin, an immune-modulating cancer therapy studied in non-small cell lung cancer and other indications. Recurring updates cover DUBLIN-3 data analyses, Plinabulin combinations with docetaxel, checkpoint inhibitors and antibody-drug conjugates, and presentations at oncology and immuno-oncology medical meetings.
Company news also includes periodic financial results, annual-report announcements, capital and corporate updates, and disclosures related to BeyondSpring’s equity interest in SEED Therapeutics and molecular glue degrader programs. These updates connect the company’s research activity, clinical-development strategy and financing actions with its public-company reporting cycle.
BeyondSpring (NASDAQ:BYSI) announced a leadership transition effective July 1, 2026, aligning management around its confirmatory DUBLIN-4 Phase 3 trial of Plinabulin in post-ICI NSCLC.
Lan Huang remains Chairman; Min Qiu becomes CEO; Jen Majeti becomes Vice Chairman; Na Li is appointed CFO, supporting execution, partnerships, and financing. The plan leverages prior DUBLIN-3 Phase 3 survival and neutropenia data and an IP portfolio for Plinabulin protected to 2036, with potential U.S. exclusivity to 2041.
BeyondSpring (NASDAQ:BYSI) reported updated Phase 2 data for pembrolizumab plus plinabulin/docetaxel in metastatic NSCLC patients progressing after first-line immune checkpoint inhibitors.
Among 47 patients, median PFS was 7.0 months, median DoR 9.3 months, DCR 79.5%, ORR 18.2%, and 12‑/24‑month OS rates 78.1% and 58.0%, with manageable safety.
BeyondSpring (NASDAQ:BYSI) will present a poster at the 2026 ASCO Annual Meeting in Chicago. The poster covers Study 303, a Phase 2 trial of plinabulin, docetaxel and pembrolizumab in metastatic NSCLC after acquired resistance to anti-PD-1/L1 therapies.
The presentation is scheduled for Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place, in the Lung Cancer – Non-Small Cell Metastatic session (Abstract 8567, Poster Board 357).
BeyondSpring (NASDAQ:BYSI) reported Q1 2026 results and pipeline updates. Continuing operations showed R&D and G&A expenses of $1.1M each, net loss of $2.4M, and $7.9M in cash and investments.
Plinabulin preclinical data supported its use with ADCs, while SEED’s ST-01156 entered Phase 1 with biomarker-driven development.
BeyondSpring (NASDAQ:BYSI) reported AACR 2026 preclinical data showing plinabulin improved complete tumor regressions, extended survival, and reduced animal deaths when combined with leading ADCs (T-DXd, Dato-DXd), with or without PD-1 inhibitors. The release cites plinabulin’s GEF-H1 mechanism and prior Phase 3 DUBLIN-3 results.
Notable clinical references: DUBLIN-3 doubled two- and three-year survival and cut grade 4 neutropenia from 33% to 5%. BeyondSpring plans a 442-patient confirmatory Phase 3 DUBLIN-4 program and highlights ADC combination opportunities.
BeyondSpring (NASDAQ: BYSI) will present a poster at the AACR Annual Meeting 2026 in San Diego on April 21, 2026. The poster, titled Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates, is scheduled for 2:00–5:00 PM PT in Poster Section 8, Poster Board 16 (Poster 5597).
The presentation appears in the Immunology session category under "T Cell Engagers 2 / Antibody-Drug Conjugates 1" and lists Yingjuan June Lu and colleagues as presenters/authors.
BeyondSpring (NASDAQ:BYSI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on March 25, 2026.
The filing includes the company’s audited consolidated financial statements and is available on the SEC website and the company’s investor site. Shareholders may request a free hard copy from Investor Relations.
BeyondSpring (NASDAQ:BYSI) reported 2025 year-end results highlighting Phase 3 success for plinabulin in EGFR wild-type NSCLC and strategic progress at SEED Therapeutics.
Key facts: DUBLIN-3 showed OS HR 0.72 (p=0.0078) with median OS +2.5 months, grade 4 neutropenia reduced to 5%, DUBLIN-4 confirmatory trial planned (NCT07361484), SEED initiated Phase 1a for ST-01156, completed $30M Series A-3, and company cash was $12.6M as of Dec 31, 2025.
BeyondSpring (NASDAQ: BYSI) will participate at the Immuno-Oncology 360° Conference in Boston, February 10-12, 2026. Dr. Lan Huang, Co-Founder, Chairman and CEO, will present on Plinabulin on February 11, 2026, 4:55–5:10 PM ET in the Sheraton Boston Grand Ballroom.
Presentation covers Plinabulin’s mechanism and translational strategy to enhance PD-1/PD-L1 blockade; slides will be posted afterward on the company’s Posters and Presentations webpage.
BeyondSpring (NASDAQ: BYSI) reported results from the Asian subset (n=488) of the global Phase 3 DUBLIN-3 trial evaluating plinabulin + docetaxel versus docetaxel in 2L/3L EGFR wild-type NSCLC presented at ESMO Asia 2025. In the Asian ITT cohort, combination therapy achieved median OS 10.8 vs 8.8 months (HR 0.81, p=0.0426). In the mechanism‑aligned non‑squamous subgroup the HR was 0.69 with a 3‑month median OS benefit (p=0.0064). The combo doubled 2‑ and 3‑year survival rates and markedly reduced docetaxel‑induced grade 4 neutropenia (DP 3.9% vs D 26.5%, p<0.0001), while maintaining favorable tolerability.